Botulinum Toxin a for the Management of Hidradenitis Suppurativa

Reilly, Daniel J; Munasinghe, Charlene P; Nizzero, Danielle; Morsi, Adel

doi:10.1177/2513826x1500100101

Cited by 2 publications

(3 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…5,78 Results from six previous case reports, one prospective analysis and one pilot RCT indicate that BTX injections may be a beneficial treatment for HS. 78,[197][198][199][200][201][202][203] Notable reductions in the number of HS lesions and patient-reported pain, healing of sinus tracts and improvements in DLQI have been reported. 78,[197][198][199][200][201][202][203] Treatment sites included the axillary, inframammary, groin and gluteal areas and treatments were repeated every 3-10 months, with no loss of efficacy.…”

Section: Botulinum Toxin Injectionsmentioning

confidence: 99%

“…78,[197][198][199][200][201][202][203] Notable reductions in the number of HS lesions and patient-reported pain, healing of sinus tracts and improvements in DLQI have been reported. 78,[197][198][199][200][201][202][203] Treatment sites included the axillary, inframammary, groin and gluteal areas and treatments were repeated every 3-10 months, with no loss of efficacy. 78,[197][198][199][200][201][202][203] No complications with BTX treatment were reported in any of the studies.…”

Section: Botulinum Toxin Injectionsmentioning

confidence: 99%

“…78,[197][198][199][200][201][202][203] Treatment sites included the axillary, inframammary, groin and gluteal areas and treatments were repeated every 3-10 months, with no loss of efficacy. 78,[197][198][199][200][201][202][203] No complications with BTX treatment were reported in any of the studies.…”

Section: Botulinum Toxin Injectionsmentioning

confidence: 99%

See 2 more Smart Citations

Practical Guidelines for Managing Patients With Hidradenitis Suppurativa: An Update

et al. 2022

View full text Add to dashboard Cite

Hidradenitis suppurativa (HS) is a chronic, inflammatory skin disease that is characterized by the formation of comedones, papules, nodules, abscesses and sinus tracts in the axillary, inframammary, groin, and gluteal areas. Up to 3.8% of the Canadian population has HS, though due to a lack of awareness of HS, many patients are initially misdiagnosed and do not receive adequate treatment early on in the disease course. Once a diagnosis of HS is made, developing an effective management plan can be a dilemma for many providers. There is significant variability in response to any given therapy within the HS patient population and many HS patients have other medical comorbidities which must be taken into consideration. The aim of this review is to provide a practical approach for all healthcare providers to diagnose and manage HS and its associated comorbidities. A sample electronic medical record template for HS management was developed by the Canadian Hidradenitis Suppurativa Foundation Executive Board and is intended for use in clinical settings. This will help to increase collaboration between primary healthcare providers, dermatologists, and other medical specialists and ultimately improve the quality of care that HS patients receive.

show abstract